Dykema Gossett PLLC

Cannabis Law Blog

Posts by David P. Graham

Cannabis Law Blog

News and analysis focusing on the full spectrum of cannabis-related issues facing businesses, investors, financial institutions and all levels of government throughout the United States

Contributors

Photo of Cannabis Law Blog David P. Graham
Senior Counsel
dgraham@dykema.com
612-486-1521
View Bio

Showing 3 posts by David P. Graham.

FDA Again Warns CBD Product Manufacturer

On July 22, 2019 the FDA sent a warning letter to Curaleaf, Inc. warning it about the labeling and marketing of its CBD products including lotion, patches, tinctures, disposable vape pen, and pet products. FDA concluded that Curaleaf’s websites, social media and other marketing material made unsupported health claims about its products, in violation of FDA regulations.  Read More ›

CBD Warning Letter

FDA sent warning letters dated March 28 to three companies marketing CBD products with what FDA describes as “egregious and unfounded claims that are aimed at vulnerable populations.” The companies which received warning letters sell hemp oil, CBD soft gels, CBD crystal isolate and other related products. Read More ›

FDA Statement on Cannabis-Containing and Cannabis-Derived Products

On April 2, 2019, the FDA further described its upcoming effort to regulate or at least discuss the regulation of cannabis-containing and cannabis-derived products. The FDA reiterated its power as given to it by the 2018 Farm Bill to regulate cannabis products and to ensure that they are used and sold safely in drugs, dietary supplements and conventional food. Read More ›